You are here: Industry Insights > investors

News List

Happiness Biotech Announces Registered Direct Offering of up to 4.2 Million Ordinary Shares to Strategic Investors prnasia
January 05, 2021
Happiness Biotech Group Limited, an innovative China-based nutraceutical and dietary supplements producer, announced that it has entered into a securities purchase agreement with certain non-U.S. strategic investors for a registered direct placement.
Investors led by former CEO offer $3.9B for plasma producer China Biologic fiercepharma
August 23, 2018
Nasdaq-listed China Biologic Products received its second buyout offer in less than three months. (Nasdaq)
Spooked AbbVie investors are selling off shares—but do they need to be? fiercepharma
July 23, 2018
AbbVie investors are running for the exits after comments on biosimilars from the FDA head, proposed rebate rule changes from the Trump administration and an ominous short-seller tweet. But they don’t need to be, industry watchers say.
Why did Merck issue an unusual press release? It knows investors are hyperfocused on I-O data fiercepharma
May 08, 2018
Investor “conspiracy theories” are real in immuno-oncology, something Merck & Co. knows all too well. So well, in fact, that the company recently changed up its communications game to address investor fears directly.
Exasperated Allergan investors recruiting activists to push for asset sales fiercepharma
April 28, 2018
Investors aren’t happy with the steps Allergan has taken to try to remedy its share-price slump—and they’re calling on outsiders to help stir things up.
Envisagenics receives Dynamk Capital investment in support of AI drug discovery pharmaasia
December 06, 2017
Dynamk has invested US$500,000 in Envisagenics, which applies artificial intelligence to the genetic sequence of patients to discover new therapies.